Efficacy of Nemiralisib in Chronic Obstructive Pulmonary Disease: A Systematic Review

Clin Ther. 2024 Mar 18:S0149-2918(24)00064-X. doi: 10.1016/j.clinthera.2024.02.008. Online ahead of print.ABSTRACTPURPOSE: Chronic obstructive pulmonary disease (COPD) is a major public health concern. Exacerbation of COPD leads to poor health and frequent episodes of increased systemic and airway inflammation. Immunomodulatory drugs have garnered extensive attention because they may reduce the rate of COPD exacerbation. This review aimed to evaluate the efficacy and safety of nemiralisib in COPD patients.METHODS: Medical databases, including the Cochrane Library, EMBASE, and PubMed, were queried from inception to June 2023 to identify randomized controlled trials (RCTs) on the efficacy of nemiralisib in COPD patients. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The Cochrane Collaboration tool was used to assess the risk of bias of the included RCTs. Two authors independently conducted literature screening and data extraction. Key information from the included studies was extracted, tabulated, and compared using a data extraction table. Moreover, the key characteristics, quality, potential bias, and endpoint outcomes of the included studies were summarized. A meta-analysis was conducted when the study outcomes were sufficiently comparable, and the required data were available for extraction.FINDINGS: Initially, 48 references were identified, leading to the inclusion of four trials. No sig...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research